A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

NCT06164951 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Achondroplasia

Interventions

DRUG: Infigratinib 0.25 mg/kg/day
DRUG: Placebo Comparator 0.25 mg/kg/day

Sponsor

QED Therapeutics, a BridgeBio company